A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Study sponsor: Palvella Therapeutics, Inc. · PVLA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-06-30Actual
Enrollment · participants87Actual
Source updated2024-08-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.